Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.
D000284:Administration, Oral; D019540:Area Under Curve; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006207:Half-Life; D006801:Humans; D016014:Linear Models; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D013450:Sulfones / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D013997:Time Factors
C486877:3-(3-(methylsulfonyl)phenyl)-1-piperidine; C486876:3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine; D065127:Dopamine D2 Receptor Antagonists; D010880:Piperidines; D017448:Receptors, Dopamine D2; D013450:Sulfones; D019389:Cytochrome P-450 CYP2D6